Clinical Trial Update: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment [Phase 3]

View source ↗

Summary

Phase 3 maintenance trial evaluating cognitive-behavioral therapy combined with lisdexamfetamine (LDX) for binge-eating disorder and obesity has completed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder
• Obesity

Drugs mentioned

• Vyvanse (lisdexamfetamine dimesylate)

Snippet

Sponsor: Yale University | Conditions: Binge-Eating Disorder, Obesity | Phase 3 | Status: COMPLETED | Results posted: 2025-12-17